353 related articles for article (PubMed ID: 18756899)
1. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
[TBL] [Abstract][Full Text] [Related]
2. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
Pavićević R; Milicić J; Bubanović G; Supe S
Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
4. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
Chantapet P; Riantawan P; Lebnak P; Getngern P
J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
[TBL] [Abstract][Full Text] [Related]
5. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
Zissimopoulos A; Stellos K; Permenopoulou V; Petrakis G; Theodorakopoulos P; Baziotis N; Thalassinos N
Hell J Nucl Med; 2007; 10(1):62-6. PubMed ID: 17450257
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
Lung; 2001; 179(1):57-65. PubMed ID: 11479694
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
8. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
9. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
10. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
[TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
12. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].
Mroczko B; Szmitkowski M; Czygier M
Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186
[TBL] [Abstract][Full Text] [Related]
13. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
15. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
16. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation.
Giovanella L; Ceriani L; Bandera M; Rimoldi R; Beghé B; Roncari G
Q J Nucl Med; 1995 Dec; 39(4):285-9. PubMed ID: 8624791
[TBL] [Abstract][Full Text] [Related]
17. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
18. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
20. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]